ADT1759-Human Anti-CD3xCD20 Bispecific Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1759 |
Product Name |
ADT1759-Human Anti-CD3xCD20 Bispecific Antibody |
Isotype |
Human IgG1-Kappa |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3 mAb, Anti-CD3 Monoclonal Antibody, CD3 recombinant antibody, Anti-CD3 Bispecific Antibody, Human Anti-CD20 mAb, CD20 recombinant antibody, Anti-CD20 Monoclonal Antibody, Anti-CD20 Bispecific Antibody |
|
Official Symbol |
CD20xCD3 |
Target 1 |
CD20 |
Gene ID 1 |
931 |
Target 2 |
CD3 |
Gene 2 |
916 |
Species |
Human |
Drug Name |
Mosunetuzumab |
CAS Number |
1905409-39-3 |
Chemical Formula |
C6515H10031N1725O2025S43 |
Product Description |
Mosunetuzumab is a humanized anti-CD20/CD3 bispecific antibody used to treat relapsed or refractory follicular lymphoma. |
Mechanism of Action |
Mosunetuzumab is a full-length, humanized anti-CD20/CD3 bispecific antibody that targets CD20-expressing B-cells. Mosunetuzumab recruits T-cells and leads to their activation by promoting the formation of an immunologic synapse between a target B-cell and a cytotoxic T-cell. The activation of T-cells leads to the directed release of perforin and granzymes through the immunologic synapsis, which ultimately induces B-cell lysis and cell death. |
Metabolism |
Mosunetuzumab is a protein therapeutic. It is expected to be degraded into small peptides and amino acids via catabolic pathways. |
Molecular Weight |
146.3 KDa |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4,Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL: Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16.
2. Salvaris R, Ong J, Gregory GP: Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J Pers Med. 2021 Apr 29;11(5). pii: jpm11050355. doi: 10.3390/jpm11050355. |
FAQ
-
+ -
What is CD3, and why is it important in immunotherapy?
CD3 is a protein complex found on T cells that plays a crucial role in T cell activation and immune responses. It is a key target for bispecific antibodies, such as CD3x tumor antigen bispecifics, which recruit T cells to kill cancer cells.
-
+ -
How can I obtain Request Quote of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
Why is CD20 a significant target in B-cell malignancies?
CD20 is a surface protein expressed on B cells and is a key target for treating diseases like non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Anti-CD20 monoclonal antibodies, such as rituximab, help deplete B cells through immune-mediated mechanisms. -
+ -
How are bispecific antibodies evaluated in preclinical studies?
Assays include binding affinity (SPR/BLI), cell-based cytotoxicity, pharmacokinetics, and toxicity profiling in animal models.